In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How GSK Is Driving Early Stage Research In Its DPUs

Executive Summary

Most of GlaxoSmithKline's early stage research organizations, discovery performance units, survive a three-year review cycle, with co-localization, monetary incentives and career support leading a change of culture.

Advertisement

Related Content

Rebuilding Big Pharma R&D: An Interview With GSK’s Ian Tomlinson
GSK Offers a Window Into Attempts at Biotech-like R&D
GSK Says R&D Productivity Up, But Story Is About Culture, Not Numbers
GSK Spins Out Pain Assets, Raises $35.4m
GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal
GSK’s Witty Looks To Biotech Model In R&D Retool; Mini Labs Will Bid For Project Funding

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel